tetano
Editor, Senior Moderator
Clin Pathol
. 2022 Sep 20;15:2632010X221124908.
doi: 10.1177/2632010X221124908. eCollection 2022 Jan-Dec.
Characteristics of the SARS-CoV-2 Omicron (B.1.1.529) Variant and Emerging Impact on Global Public Health
Md Rabiul Islam[SUP] 1 [/SUP], Waheeda Nasreen[SUP] 1 [/SUP], Ramisa Anjum[SUP] 1 [/SUP], Mohammad Shahriar[SUP] 1 [/SUP], Arpita Roy[SUP] 2 [/SUP], Kuldeep Dhama[SUP] 3 [/SUP], Mohiuddin Ahmed Bhuiyan[SUP] 1 [/SUP]
Affiliations
Abstract
The discovery of the SARS-CoV-2 Omicron (B.1.1.529) variant has sparked alarm globally because of its rapid rate of infection and trespassing acquired immunity due to vaccination or natural infection. This heavily mutated variant is rapidly spreading around the world. Infected individuals with the Omicron variant may suffer from flu-like symptoms, and infected with the Delta variant frequently report low oxygen levels, high pulse rates, and a loss of smell and taste. Also, the Omicron variant causes asymptomatic or mild disease so far, and not any severe illness as like Delta, and this new variant has a 15% to 80% reduced risk of hospitalization than the Delta variant. Scientists are worried about the possibility of escaping the immunity by the Omicron variants and subvariants among fully vaccinated and recovered COVID-19 patients. Two doses of available vaccines are found to be partially ineffective in protecting this new variant, therefore, the third dose as a booster is recommended to enhance antibody level. Moreover, some antiviral drugs significantly reduce hospitalization or death among mild to severe COVID-19 patients. All authorized antiviral drugs are effective against viral replication for most SARS-CoV-2 variants, and particularly some monoclonal antibodies may not now be effective in treating COVID-19 patients. There is an urgent need to update existing vaccines, develop more effective and newer vaccines as well as additional monoclonal antibodies to counter Omicron. Therefore, along with close monitoring of Omicron characteristics, the present study suggests that health safety guidelines, mass immunization, early diagnosis, and search for effective antiviral drugs should be the approaches to fight against newer SARS-CoV-2 variants.
Keywords: B.1.1.529; COVID-19; COVID-19 vaccines; Coronavirus; Omicron; SARS-COV-2 variants; SARS-CoV-2; antiviral agents.
. 2022 Sep 20;15:2632010X221124908.
doi: 10.1177/2632010X221124908. eCollection 2022 Jan-Dec.
Characteristics of the SARS-CoV-2 Omicron (B.1.1.529) Variant and Emerging Impact on Global Public Health
Md Rabiul Islam[SUP] 1 [/SUP], Waheeda Nasreen[SUP] 1 [/SUP], Ramisa Anjum[SUP] 1 [/SUP], Mohammad Shahriar[SUP] 1 [/SUP], Arpita Roy[SUP] 2 [/SUP], Kuldeep Dhama[SUP] 3 [/SUP], Mohiuddin Ahmed Bhuiyan[SUP] 1 [/SUP]
Affiliations
- PMID: 36147794
- PMCID: PMC9490387
- DOI: 10.1177/2632010X221124908
Abstract
The discovery of the SARS-CoV-2 Omicron (B.1.1.529) variant has sparked alarm globally because of its rapid rate of infection and trespassing acquired immunity due to vaccination or natural infection. This heavily mutated variant is rapidly spreading around the world. Infected individuals with the Omicron variant may suffer from flu-like symptoms, and infected with the Delta variant frequently report low oxygen levels, high pulse rates, and a loss of smell and taste. Also, the Omicron variant causes asymptomatic or mild disease so far, and not any severe illness as like Delta, and this new variant has a 15% to 80% reduced risk of hospitalization than the Delta variant. Scientists are worried about the possibility of escaping the immunity by the Omicron variants and subvariants among fully vaccinated and recovered COVID-19 patients. Two doses of available vaccines are found to be partially ineffective in protecting this new variant, therefore, the third dose as a booster is recommended to enhance antibody level. Moreover, some antiviral drugs significantly reduce hospitalization or death among mild to severe COVID-19 patients. All authorized antiviral drugs are effective against viral replication for most SARS-CoV-2 variants, and particularly some monoclonal antibodies may not now be effective in treating COVID-19 patients. There is an urgent need to update existing vaccines, develop more effective and newer vaccines as well as additional monoclonal antibodies to counter Omicron. Therefore, along with close monitoring of Omicron characteristics, the present study suggests that health safety guidelines, mass immunization, early diagnosis, and search for effective antiviral drugs should be the approaches to fight against newer SARS-CoV-2 variants.
Keywords: B.1.1.529; COVID-19; COVID-19 vaccines; Coronavirus; Omicron; SARS-COV-2 variants; SARS-CoV-2; antiviral agents.